Optimal Prevention of Overdose Deaths and Opioid Relapse Following Discharge: A Multi-Center RCT of Naltrexone Versus Buprenorphine in Norway

Trial Profile

Optimal Prevention of Overdose Deaths and Opioid Relapse Following Discharge: A Multi-Center RCT of Naltrexone Versus Buprenorphine in Norway

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Naltrexone (Primary) ; Buprenorphine/naloxone
  • Indications Opioid abuse
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2017 New trial record
    • 18 Oct 2017 Results published in the JAMA Psychiatry
    • 18 Oct 2017 Co-primary endpoint has been met (Days of use or abstinence from opioids), according to an Alkermes plc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top